- Home
- NREF vs AVIR Comparison
NREF vs AVIR Comparison
Compare NREF & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NREF
- AVIR
- Stock Information
- Founded
- NREF 2019
- AVIR 2012
- Country
- NREF United States
- AVIR United States
- Employees
- NREF N/A
- AVIR N/A
- Industry
- NREF Real Estate Investment Trusts
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- NREF Real Estate
- AVIR Health Care
- Exchange
- NREF Nasdaq
- AVIR Nasdaq
- Market Cap
- NREF 242.2M
- AVIR 273.7M
- IPO Year
- NREF 2020
- AVIR 2020
- Fundamental
- Price
- NREF $14.37
- AVIR $2.72
- Analyst Decision
- NREF Hold
- AVIR Hold
- Analyst Count
- NREF 4
- AVIR 1
- Target Price
- NREF $14.25
- AVIR $6.00
- AVG Volume (30 Days)
- NREF 43.4K
- AVIR 487.6K
- Earning Date
- NREF 05-01-2025
- AVIR 05-13-2025
- Dividend Yield
- NREF 14.02%
- AVIR N/A
- EPS Growth
- NREF N/A
- AVIR N/A
- EPS
- NREF 2.69
- AVIR N/A
- Revenue
- NREF $108,951,000.00
- AVIR N/A
- Revenue This Year
- NREF $24.31
- AVIR N/A
- Revenue Next Year
- NREF $5.86
- AVIR N/A
- P/E Ratio
- NREF $5.30
- AVIR N/A
- Revenue Growth
- NREF 325.97
- AVIR N/A
- 52 Week Low
- NREF $12.14
- AVIR $2.60
- 52 Week High
- NREF $18.09
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- NREF 51.08
- AVIR 39.17
- Support Level
- NREF $14.07
- AVIR $2.66
- Resistance Level
- NREF $14.66
- AVIR $3.08
- Average True Range (ATR)
- NREF 0.50
- AVIR 0.13
- MACD
- NREF 0.10
- AVIR -0.02
- Stochastic Oscillator
- NREF 70.11
- AVIR 14.29
About NREF NexPoint Real Estate Finance Inc.
NexPoint Real Estate Finance Inc is a real estate investment trust. The company provides structured financing solutions by investing in mid-sized multifamily, storage and select-service, and extended-stay hospitality properties. Its investment objective is to generate attractive, risk-adjusted returns for stockholders over the long term. The Company is focused on originating, structuring and investing in first-lien mortgage loans, mezzanine loans, preferred equity, convertible notes, multifamily properties, and common equity investments, as well as multi-family and single-family rental ("SFR") commercial mortgage-backed securities securitizations ("CMBS securitizations"), multifamily structured credit risk notes ("MSCR Notes") and mortgage-backed securities.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).